Stock DXB DIMERIX LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Dimerix Limited

Equities

DXB

AU000000DXB7

Market Closed - Australian S.E.
Other stock markets
 07:10:08 25/06/2024 BST 		5-day change 1st Jan Change
0.53 AUD +1.92% Intraday chart for Dimerix Limited -13.82% +158.54%
05-29 Euroz Hartleys Adjusts Dimerix’s Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy MT
05-27 Dimerix Signs License Deal for Kidney Disease Medication in the Middle East MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Euroz Hartleys Adjusts Dimerix’s Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy
MT
Dimerix Signs License Deal for Kidney Disease Medication in the Middle East
MT
Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication
MT
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter
MT
Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target
MT
Dimerix Raises AU$20 Million for Kidney Disease Study
MT
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo
MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Dimerix Limited Announces Appointment of Mark Diamond as Director
CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%
MT
Dimerix Appoints Nonexecutive Chair
MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights
MT
Dimerix Appoints Medical Chief
MT
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer
CI
ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand
AQ
Softer US Employment Data End Australian Shares' Three-Day Losing Streak
MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug
MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name
MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia
MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DXB Stock
  4. News Dimerix Limited